Nanjing Bioheng Biotech Co., Ltd.

Nanjing Bioheng Biotech Co., Ltd., established in March 2017 with a registered capital of 8.947296 million RMB, is an innovative biomedical company focusing on disease treatment and service. It is co-founded by doctors from top universities at home and abroad and operation teams with rich business experience. Its business covers immunotherapy, gene therapy and CRO services. The founding team of the company is from Professor Carl June from the University of Pennsylvania, USA, the father of cell therapy. It is the inventor of the fifth generation of universal cart technology in the world. It is a global leader in gene editing, cell transformation, process preparation and quality control system. At present, Bioheng is developing five pipelines including CTA101, CTA 301, CTC101, CTD101 and CTB101. For hematoma and solid tumor, the first universal cart 19 for acute leukemia has carried out clinical trials in many hospitals, and has shown good results in treating patients. It is expected to submit IND application in 2020, which is expected to become the first universal cart treatment company in China. Based on the company's advanced technology and platform, we have reached in-depth cooperation with Children's Hospital of Philadelphia, Penn University, Korean Toolgen and Shanghai University of Science and Technology.

At present, the company has obtained financing of 130 million RMB, and has applied for 14 core patents related to the project: 12 Chinese patents, including 11 invention patents (4 authorized), 1 design patent (1 authorized), 2 international patents (PCT) and 1 SCI paper. The patent for the preparation of universal Car-T products applied by the company has been authorized by China Patent Office, which is the first in China and the second in the world. The company has been selected into Jiangsu Province's "entrepreneurship and innovation talents" plan, Jiangbei New Area's high-level entrepreneurial talents introduction plan, Nanjing Overseas Students preferential subsidy project, etc., and has passed the qualification certification of national science and technology-based small and medium-sized enterprises and Jiangsu Province's high-tech enterprise cultivation library.